Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Clinical Oncology: Case Reports
Matthias Mezger Author
Subjects of specialization
Affiliation
cancer, cancer oncology, Carcinogenesis
Departments of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lubeck, Lubeck, Germany
Biography
Dr. Matthias Mezger is working as scientist and professor at Departments of Cardiology, Angiology and Intensive Care Medicine, University Heart Center Lubeck, Lubeck, Germany. The author has specalization in cancer, cancer oncology, chemotherapy, Carcinogenesis, Chemotherapy
Publications
Case Report Subscription
Autoimmune Toxicity Following Nivolumab and Ipilimumab Therapy For Hepatocellular Carcinoma-An Interdisciplinary Challenge
Author(s): Matthias Mezger, Cara Harms, Karolin Schmoll, Aneke Gansewig, Ingo Eitel, Nikolas von Bubnoff and Tobias Graf
Abstract
Over the last years, several new drugs have been launched for the treatment of cancer. Immune checkpoint blockade suppresses intrinsic down-regulators of immunity, such as cytotoxic T-lymphocyte Antigen 4 (CTLA-4) and Programmed Cell Death 1 (PD-1) or its ligand, Programmed Cell Death Ligand 1 (PD-L1). Immune checkpoint blockade enhances patient´s immune system and increased survival rates for different cancer subtypes. However, immune checkpoint blockade can lead to autoimmunity with a multitude of side effects that involve the heart, gastrointestinal tract, endocrine glands, skin, CNS and liver. We here present the case of a patient who was admitted to the emergency department with stroke- like symptoms. Whilst monitoring on stroke- unit was o... view more»
Google Scholars / Researchers Sites
